pindolol has been researched along with carvedilol in 23 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (13.04) | 18.7374 |
| 1990's | 4 (17.39) | 18.2507 |
| 2000's | 10 (43.48) | 29.6817 |
| 2010's | 6 (26.09) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Carrupt, PA; Gaillard, P; Schambel, P; Testa, B | 1 |
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Carrupt, PA; Guillarme, D; Henchoz, Y; Rudaz, S; Veuthey, JL | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Bednarski, M; Dybała, M; Filipek, B; Groszek, G | 1 |
| He, Z; Li, H; Liu, J; Liu, X; Sui, X; Sun, J; Sun, Y; Yan, Z | 1 |
| Bard, B; Carrupt, PA; Martel, S | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| Gozalbes, R; Pineda-Lucena, A | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Bristow, MR; Handwerger, D; Klein, J; Larrabee, P; Minobe, W; Müller-Beckmann, B; Port, JD; Roden, R; Skerl, L | 2 |
| Adam, W; Anderson, A; Cripps, J; Morgan, TO | 1 |
| Cronin, CJ; Graham, BR; Prichard, BN; Tomlinson, B | 1 |
| Gordin, A; Sundberg, S; Tiihonen, K | 1 |
| Lefflerová, K; Widimský, J | 1 |
| Doze, P; Elsinga, PH; Maas, B; Vaalburg, W; Van Waarde, A; Wegman, T | 1 |
| Bednarski, M; Filipek, B; Groszek, G; Szafarz, M; Szymura-Oleksiak, J; Walczak, M | 1 |
| Pisklak, DM; Wawer, I; Zielińska-Pisklak, MA | 1 |
2 review(s) available for pindolol and carvedilol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Betablockers in the treatment of hypertension (with special emphasis on betablockers with ISA). A review.
Topics: Adrenergic beta-Antagonists; Aged; Carbazoles; Carvedilol; Celiprolol; Humans; Hypertension; Labetalol; Middle Aged; Pindolol; Propanolamines | 1988 |
3 trial(s) available for pindolol and carvedilol
| Article | Year |
|---|---|
The use of carvedilol in elderly hypertensive patients.
Topics: Adrenergic beta-Antagonists; Adult; Age Factors; Aged; Aged, 80 and over; Blood Pressure; Carbazoles; Carvedilol; Female; Half-Life; Heart Rate; Humans; Hypertension; Lipids; Male; Metoprolol; Middle Aged; Multicenter Studies as Topic; Nitrendipine; Pindolol; Propanolamines; Random Allocation; Single-Blind Method | 1990 |
Haemodynamics of carvedilol in normal subjects compared with propranolol, pindolol, and labetalol.
Topics: Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Dose-Response Relationship, Drug; Double-Blind Method; Heart Rate; Hemodynamics; Humans; Labetalol; Male; Physical Exertion; Pindolol; Propanolamines; Propranolol; Random Allocation | 1987 |
Vasodilatory effects of carvedilol and pindolol.
Topics: Adrenergic beta-Antagonists; Adult; Blood Pressure; Carbazoles; Carvedilol; Double-Blind Method; Female; Heart Rate; Humans; Male; Pindolol; Propanolamines; Random Allocation; Respiration; Vascular Resistance; Vasodilation | 1987 |
18 other study(ies) available for pindolol and carvedilol
| Article | Year |
|---|---|
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
Topics: Indoles; Ligands; Models, Molecular; Molecular Conformation; Molecular Structure; Piperazines; Propanolamines; Receptors, Serotonin; Receptors, Serotonin, 5-HT1; Serotonin; Structure-Activity Relationship; Tetrahydronaphthalenes | 1996 |
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
High-throughput log P determination by ultraperformance liquid chromatography: a convenient tool for medicinal chemists.
Topics: Chemical Phenomena; Chemistry, Pharmaceutical; Chemistry, Physical; Chromatography, Liquid; Mathematics; Pharmaceutical Preparations; Software | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Synthesis and adrenolytic activity of 1-(1H-indol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol and its enantiomers. Part 1.
Topics: 2-Propanol; Adrenergic Antagonists; Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Electrocardiography; Hypotension; Indoles; Parasympatholytics; Propanolamines; Propanols; Rabbits; Rats; Receptors, Adrenergic; Receptors, Adrenergic, alpha-1; Receptors, Adrenergic, beta-1; Spasm; Stereoisomerism | 2009 |
First-principle, structure-based prediction of hepatic metabolic clearance values in human.
Topics: Computational Biology; Drug Discovery; Hepatocytes; Humans; Hydrogen-Ion Concentration; Liver; Metabolic Clearance Rate; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship; Sensitivity and Specificity; Software | 2009 |
Lipophilicity of basic drugs measured by hydrophilic interaction chromatography.
Topics: Chemistry, Pharmaceutical; Chromatography; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Pharmaceutical Preparations; Solubility; Technology, Pharmaceutical | 2009 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
QSAR-based solubility model for drug-like compounds.
Topics: Databases, Factual; Models, Molecular; Pharmaceutical Preparations; Quantitative Structure-Activity Relationship; Solubility; Water | 2010 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Effects of carvedilol on adrenergic receptor pharmacology in human ventricular myocardium and lymphocytes.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Binding, Competitive; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Culture Techniques; Cyclic AMP; Heart Failure; Heart Ventricles; Humans; Iodocyanopindolol; Lymphocytes; Myocardium; Pindolol; Propanolamines; Receptors, Adrenergic, alpha; Receptors, Adrenergic, beta; Vasodilator Agents | 1992 |
Receptor pharmacology of carvedilol in the human heart.
Topics: Adrenergic beta-Antagonists; Antihypertensive Agents; Binding, Competitive; Carbazoles; Cardiomyopathy, Dilated; Carvedilol; Cyclic AMP; Guanylyl Imidodiphosphate; Humans; Iodocyanopindolol; Metoprolol; Myocardium; Pindolol; Propanolamines; Propranolol; Receptors, Adrenergic, beta; Vasodilator Agents | 1992 |
Synthesis and evaluation of radiolabeled antagonists for imaging of beta-adrenoceptors in the brain with PET.
Topics: Adrenergic beta-Antagonists; Animals; Brain; Bupranolol; Carbazoles; Carbon Radioisotopes; Carvedilol; Fluorine Radioisotopes; Male; Models, Animal; Organ Specificity; Pindolol; Propanolamines; Propranolol; Radioligand Assay; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Tissue Distribution; Tomography, Emission-Computed | 2002 |
Application of liquid chromatography-tandem mass spectrometry method for the analysis of new nonselective beta-adrenergic blocker 1-(1-H-indol-4-yloxy)-3-{[2-(2-methoxy phenoxy)ethylo]amino}propan-2-ol (2F109) in rat plasma.
Topics: Adrenergic beta-Antagonists; Animals; Carbazoles; Carvedilol; Chromatography, High Pressure Liquid; Drug Design; Drug Stability; Male; Pindolol; Propanolamines; Quality Control; Rats; Rats, Wistar; Stereoisomerism; Tandem Mass Spectrometry | 2007 |
1H and 13C NMR characteristics of β-blockers.
Topics: Acebutolol; Acids; Adrenergic beta-Antagonists; Alkalies; Alprenolol; Atenolol; Carbazoles; Carbon Isotopes; Carvedilol; Nuclear Magnetic Resonance, Biomolecular; Pindolol; Propanolamines; Propranolol; Protons; Timolol | 2011 |